Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phlogosam is a topical anti-inflammatory ointment containing samarium sulfosalicylate as its active ingredient. Developed and marketed by the Hungarian pharmaceutical company PannonPharma, it is indicated for the treatment of various inflammatory skin conditions, including eczema, contact dermatitis, and superficial (first-degree) burns. The active ingredient, samarium sulfosalicylate, is a lanthanide salt that exhibits anti-inflammatory and astringent properties, likely by stabilizing cell membranes and reducing capillary permeability. It is an approved and marketed product in Hungary, often used to alleviate redness, swelling, and pain associated with skin irritation and minor injuries.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on samarium sulfosalicylate.